Recruiting Schizophrenia Studies in Cleveland
About Schizophrenia Clinical Trials in Cleveland
Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.
There are currently 1 schizophrenia clinical trials recruiting participants in Cleveland, OH. These studies are seeking a combined 30 participants. Research is being sponsored by Case Western Reserve University. Clinical trial participation is free and participants receive study-related medical care at no cost.
Schizophrenia Clinical Trials in Cleveland — FAQ
Are there schizophrenia clinical trials in Cleveland?
Yes, there are 1 schizophrenia clinical trials currently recruiting in Cleveland, OH. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Cleveland?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cleveland research site will contact you about next steps.
Are clinical trials in Cleveland free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cleveland studies also compensate for your time and travel.
What schizophrenia treatments are being tested?
The 1 active trials in Cleveland are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.
Data updated October 16, 2026 from ClinicalTrials.gov